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Abstract: Chronic migraine has been related to the entrapment of the supratrochlear nerve 
within the corrugator supercilii muscle. Recently, research has shown that people who have 
undergone botulinum neurotoxin A injection in frontal regions reported disappearance or 
alleviation of their migraines. There have been numerous anatomical studies conducted on 
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Caucasians revealing possible anatomical problems leading to migraine; on the other hand, 
relatively few anatomical studies have been conducted on Asians. Thus, the aim of the 
present study was to determine the topographic relationship between the supratrochlear 
nerve and corrugator supercilii muscle in the forehead that may be the cause of migraine. 
Fifty-eight hemifaces from Korean and Thai cadavers were used for this study. The 
supratrochlear nerve entered the corrugator supercilii muscle in every case. Type I, in which 
the supratrochlear nerve emerged separately from the supraorbital nerve at the medial  
one-third portion of the orbit, was observed in 69% (40/58) of cases. Type II, in which the 
supratrochlear nerve emerged from the orbit at the same location as the supraorbital nerve, 
was observed in 31% (18/58) of cases. 
Keywords: supratrochlear nerve; corrugator supercilii muscle; chronic migraine;  
trigger point injection; periorbital region 
 
1. Introduction 
The supratrochlear nerve (STN) and supraorbital nerve (SON) constitute the terminal branch of the 
frontal nerve, which is a major branch of the ophthalmic nerve. After passing over the roof of the orbit 
anteromedially, the STN and SON travel through the corrugator supercilii muscle (CSM) and proceed 
to the frontal belly of the occipitofrontalis muscle to receive the sensation of the mucosa of the glabella, 
upper eyelid, and skin of the lower forehead close to the midsagittal line [1,2]. 
The STN and SON are anesthetized prior to performing various surgical procedures [3,4].  
For example, the nerve-block procedure and botulinum toxin type A (BTX-A) injection can be beneficial 
for treating primary headache disorder [5–15]. BTX-A is routinely administered as a treatment for 
chronic migraine in the frontal region [9,13,15]. The trigger point is generally targeted as the injection 
site for the BTX-A treatment to relieve the associated pain [16,17]. In the frontal region, chronic 
migraine may occur as a result of entrapment of the STN by the CSM; the STN could also be compressed 
by hyperactivity of the CSM [5,9]. Since the STN is thought to be a trigger point for headache in the 
frontal region [18,19], BTX-A injection is broadly performed in the supraorbital area. However, there 
has been little research to determine the most effective BTX-A injection point based on detailed 
knowledge of the anatomical structure of the frontal area. 
In the USA, this nerve-block procedure and trigger-point injections carried out with lidocaine or 
bupivacaine have provided sustained and often rapid pain relief to patients experiencing various types 
of headache [20,21]. It has been recommended that anesthetics should be injected into the medial portion 
of the eyebrow to produce a successful nerve block of the STN [14]. However, while it is quite easy to 
find surface landmarks to enable SON block, it is quite difficult to find appropriate surface landmarks 
to enable anesthetization of the STN, despite the numerous studies describing the morphology of that 
nerve. This has resulted in numerous unnecessary injections to induce STN anesthesia in the forehead 
skin, and when it is achieved; this anesthesia is less effective compared with SON block [12,22–24]. 
Only a few of the studies that have investigated the STN morphology have described its patterns of 
emergence from the orbit and its course through the CSM. Patterns of emergence of the STN from the 
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orbit are clinically important. Thus, elucidating the potential inter-individual differences in the anatomy 
and topography of the STN in the orbit, would aid the effective anesthesia of that nerve. 
The aim of the present study was to determine the topographic relationship between the STN and 
CSM in the forehead region and to classify the patterns of emergence of the STN from the orbit and its 
course within the CSM. 
2. Results 
The emergence patterns of the STN were divided into two main types: I and II. The STNs typically 
emerged from the medial one-third portion of the orbit, running through the thin fatty tissue behind the 
orbicularis oculi muscle, and then entered CSM in every case. Type I, in which the STN emerged 
separately at the medial one-third portion of the orbit, was observed in 40 cases (69%). These cases 
could be further divided into type Ia, in which the STN entered the CSM as a single nerve branch, and 
type Ib, in which the STN bifurcated prior to entering the CSM. Types Ia and Ib were observed in  
22 (38%) and 18 (31%) cases, respectively (Figure 1). 
 
Figure 1. Photographs and schematic illustrations indicating the distribution patterns of the 
supratrochlear nerve (STN) to the corrugator supercilii muscle (CSM). In types Ia and Ib, 
the STN emerged independently from the supraorbital notch region, and then passed through 
the CSM either as a single nerve branch (type Ia) or after bifurcating into two branches prior 
to piercing the CSM (type Ib). In types IIa and IIb, the STN emerged from the supraorbital 
notch region with the supraorbital nerve (SON), and then passed through the CSM either as 
a single nerve branch (type IIa) or after bifurcating into two branches prior to piercing the 
CSM (type IIb) (S: superior, M: medial). 
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Type II, in which the STN emerged from the orbit at the same location as the SON, was observed in 
18 cases (31%). As with type I, the type II category could be further divided into two subtypes: type IIa 
(13 cases, 22.4%), where the STN entered the CSM as a single nerve branch, and type IIb (5 cases, 
8.6%), where the STN bifurcated into two branches prior to entering the CSM (Figure 1). In one case an 
accessory foramen was found medial to the supraorbital notch; a single nerve emerged from this exit and 
then entered the CSM. An extra exit for the STN was located 5 mm lateral to the midsagittal line. 
The point at which the STN entered the CSM was measured in every case, and the distance between 
the SON and STN in type I was measured. The point at which the STN entered the CSM was  
16.4 ± 4.0 mm (mean ± SD) lateral to the midsagittal line and 2.3 ± 3.9 mm superior to the supraorbital 
margin. When the STN emerged separately from the orbit, it was located 7.5 ± 2.3 mm medial to the 
SON at the level of the supraorbital margin (Figure 2). 
 
Figure 2. Location of the STN in the supraorbital notch region and within the CSM. Chronic 
migraine may develop in the location indicated by blue dots. (VL: vertical reference line, 
HL: horizontal reference line).  
3. Discussion 
Some anatomical studies have documented the exit point of the STN from the orbit, the relationship 
between the SON and STN, and the point at which these nerves enter the CSM, with a focus on clinical 
applications [12,21,23,24]. The present study revealed the branching patterns of the STN in the 
supraorbital area. 
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The STN and SON have been target nerves for nerve-block procedures to treat various types of 
headache and for local anesthesia before performing endoscopic and transpalpebral approaches in the 
forehead region [3,4]. The present study identified a previously unreported type of STN (type II),  
which was observed in 31% of the specimens, and which could be further classified into two subtypes 
(types IIa and IIb). 
In contrast, Andersen et al. [22] reported that the STN exited the orbit as a single branch in 25% of 
cases, but was composed of two or three branches in the other cases. In addition, Miller et al. [24] found 
that the STN comprised one or more branches in 30% of cases, where that nerve exited from the orbit 
medial to the SON. The findings of the present and previous studies indicate that in addition to  
appearing as a single nerve branch, the STN can also exist as two or more branches innervating the 
midforehead skin. 
In addition, the distance between the STN and SON was measured at the level of the supraorbital 
margin. The STN was situated 7.5 ± 2.3 mm medial to the supraorbital notch or the foramen along the 
supraorbital margin. In addition, the point of entrance of the STN into the CSM was 16.4 ± 4.0 lateral to 
the midsagittal line and 2.3 ± 3.9 mm superior to the supraorbital margin. The branch of the STN nearest 
to the midsagittal line was located between 8.5 and 26.7 mm from it in the present study;  
Andersen et al. [22] observed that this distance ranged between 8 and 30 mm.  
The relationship between the STN and CSM is important for a tension-type headache, because 
frontally localized headaches can be associated with nerve entrapment and compression of the peripheral 
nerve [9,18,25]. However, only a small percentage of migraine with nerve entrapment may be due to 
nerve entrapment. Yet, the STN and SON are thought to be the trigger spots in the frontal  
region [5,9,11,12,25]. Since the STN runs through the CSM in the midforehead area, it can be entrapped by 
contraction of the CSM [5,9]. BTX-A injection is used to treat chronic migraine [10,26–30]; According 
to Blumenfeld et al., they performed two injections using 5 units on each side of the CSM for the  
BTX-A injection into the CSM. The injection point is set 15 mm above the medial superior edge of the 
orbital ridge. However, there is a discrepancy in the location of the CSM and STN between Caucasians 
and Asians and it is inappropriate to apply the same techniques to Asians. Thus, it is necessary to 
compare the location (or position) of these structures to treat chronic migraine effectively.  
Janis et al. stated the STN entered the CSM approximately 15 mm superior to the supraorbital margin 
and 19 mm lateral to the midsagittal line [12]. In the present study the point of entrance of the STN into 
the CSM was 2 mm superior to the supraorbital margin and 16 mm lateral to the midsagittal line. Based 
on these results, Asians and Caucasians have different anatomical morphology of the STN piercing point 
to the CSM. In addition, Janis et al. found that in 84% of Caucasians, the STN entered the CSM; 
however, in the present study, the STN penetrated the CSM in all cases. The STN entered the CSM as a 
single nerve branch in type Ia and IIa; the STN bifurcated into two branches prior to entering the CSM 
in type Ib and IIb. These results show that it is unclear whether Caucasians would be less 
morphologically inclined to suffer from intramuscular compression than Asians. Furthermore, Asian 
patients with type Ib and IIb morphological patterns are more likely to suffer from chronic migraine than 
patients with Ia and IIa morphological patterns due to entrapment of nerve branches. 
In general, the BTX-A injection has been recommended as 5 units per corrugator supercilii muscle 
according to PREEMPT trial [8]. In the present study, the piercing point of the STN into the CSM was 
measured. Side effects are dose related in botulinum toxin therapy. We propose that injecting a lower 
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dose (for example 2.5 units) in our defined anatomical site may produce the same therapeutic effect with 
a safer side effect profile. However, clinical trials using such lower doses are necessary in order to 
confirm or refute the utility of injection at this anatomical point. 
In summary, in addition to the descriptions of the STN provided in anatomy textbooks, there are cases 
in which the nerve branches of the STN exit from the orbit along with the SON. Moreover, the STN 
could comprise either one or two branches entering the CSM. Given the different nerve patterns of the 
STN, it can be concluded that this nerve supplies the sensation to the medial part of the forehead as one 
or two branches, and that it may not only have a different exit point, but also the same exit point from 
the orbit. As show in the results, the STN’s path through the CSM was classified into four types  
(Ia, Ib, IIa, IIb). Further research should focus on the clinical significance of the anatomical variations 
among the four types. 
4. Materials and Methods 
Fifty-eight hemifaces from Korean (22 hemifaces, 9 left and 13 right; mean age, 71.8 years) and Thai 
(36 hemifaces, 17 left and 19 right; mean age 73.4 years) cadavers were used for this study. An incision 
was made at the coronal suture region. After reflecting the forehead scalp toward the orbit, a detailed 
periosteum dissection was conducted, taking extreme care not to damage the underlying frontal belly of 
the occipitofrontalis muscle, STN, SON, and CSM (Figure 3). The anatomical relationship between the 
STN and CSM was observed on the dissected specimens. 
 
Figure 3. Frontal view of the intact specimen (A) and after reflecting the scalp over toward 
the orbit (B) (S: Superior, L: Lateral). SON: supraorbital nerve; STN: supratrochlear nerve; 
CSM: corrugator supercilii muscle. 
To indicate the point where the STN enters the CSM, the midsagittal line and the line connecting both 
supraorbital margins were used as the vertical and horizontal reference lines, respectively. We used these 
two reference lines when measuring the distance between the entry points of the STN and CSM using 
digital calipers (catalog No. 500-196-20, Mituyoto, Kanagawa, Japan). 
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The course of the STN within the CSM was classified into the following four categories based on the 
type of emergence of the STN from the orbit (Figure 4): 
Type Ia:  The STN emerges independently from the supraorbital notch region, and passes through 
the CSM as a single nerve branch. 
Type Ib:  The STN emerges independently from the supraorbital notch region, and bifurcates into 
two branches prior to entering the CSM. 
Type IIa:  The STN emerges from the supraorbital notch region with the SON and passes through 
the CSM as a single nerve branch. 
Type IIb: The STN emerges from the supraorbital notch region with the SON and then bifurcates 
into two branches prior to entering the CSM. 
 
Figure 4. Schematic illustrations showing the four patterns of the STN within the CSM. 
5. Conclusions 
The findings of the present study indicate that in addition to appearing as a single nerve branch,  
the STN can also exist as two or more branches innervating the midforehead skin. The point at which 
the STN enters the CSM can be regarded as a trigger point in the frontal region.  
Acknowledgments 
This work was partially supported by the Yonsei University Future-Leading Research Initiative of 
2014. The authors thank Ju-Yong Lee (BA) at New York University College of Dentistry and  
Hwi Eun Hur at Davidson College for assisting in revising the manuscript. 
Author Contributions 
Hyung-Jin Lee and Kwang-Seok Choi performed the dissections and drafted the overall research plan, 
including data acquisition, photographic illustrations, and drafting and revising the manuscript.  
Sung-Yoon Won performed the experiments, analyzed data, and organized resources. Prawit Apinuntrum 
provided clinical opinions about drafting and revising the Discussion section of the manuscript.  
Kyung-Seok Hu acquired data and provided anatomical knowledge. Seong-Taek Kim planned the 
research from a clinical viewpoint and provided clinical knowledge. Tanvaa Tansatit provided 
anatomical and clinical advice for the final revision of the manuscript. Hee-Jin Kim supervised the 
Toxins 2015, 7 2636 
 
 
overall organization and direction of the research, provided anatomical and clinical advice, and 
performed the final revision of the manuscript.  
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Moore, K.L.; Dalley, A.F. Clinically Oriented Anatomy, 5th ed.; Lippincott Williams & Wilkins: 
Philadelphia, PA, USA, 2006. 
2. Standring, S.; Gray, H. Gray’s Anatomy the Anatomical Basis of Clinical Practice, 40th ed.; 
Churchill Livingstone: Edinburgh, UK, 2008. 
3. Afifi, A.M.; Alghoul, M.; Zor, F.; Kusuma, S.; Zins, J.E. Comparison of the transpalpebral and 
endoscopic approaches in resection of the corrugator supercilii muscle. Aesthet. Surg. J. 2012, 32, 
151–156. 
4. Bidros, R.S.; Salazar-Reyes, H.; Friedman, J.D. Subcutaneous temporal browlift under local 
anesthesia: A useful technique for periorbital rejuvenation. Aesthet Surg. J. 2010, 30, 783–788. 
5. Behmand, R.A.; Tucker, T.; Guyuron, B. Single-Site botulinum toxin type a injection for 
elimination of migraine trigger points. Headache 2003, 43, 1085–1089. 
6. Ducic, I.; Felder, J.M., 3rd; Fantus, S.A. A systematic review of peripheral nerve interventional 
treatments for chronic headaches. Ann. Plast. Surg. 2014, 72, 439–445. 
7. Robbins, M.S.; Kuruvilla, D.; Blumenfeld, A.; Charleston, L., 4th; Sorrell, M.; Robertson, C.E.; 
Grosberg, B.M.; Bender, S.D.; Napchan, U.; Ashkenazi, A. Trigger point injections for headache 
disorders: Expert consensus methodology and narrative review. Headache 2014, 54, 1441–1459. 
8. Liberini, P.; Pari, E.; Gazzina, S.; Caratozzolo, S.; Rao, R.; Padovani, A. Technique of injection of 
onabotulinumtoxin A for chronic migraine: The PREEMPT injection paradigm. Neurol. Sci. 2014, 
35 (Suppl. 1), 41–43. 
9. De Ru, J.A.; Buwalda, J. Botulinum toxin A injection into corrugator muscle for frontally  
localised chronic daily headache or chronic tension-type headache. J. Laryngol. Otol. 2009, 123, 
412–417. 
10. Dodick, D.; Blumenfeld, A.; Silberstein, S.D. Botulinum neurotoxin for the treatment of migraine 
and other primary headache disorders. Clin. Dermatol. 2004, 22, 76–81. 
11. Guyuron, B.; Varghai, A.; Michelow, B.J.; Thomas, T.; Davis, J. Corrugator supercilii muscle 
resection and migraine headaches. Plast Reconstr. Surg. 2000, 106, 429–434; discussion 435–437. 
12. Janis, J.E.; Hatef, D.A.; Hagan, R.; Schaub, T.; Liu, J.H.; Thakar, H.; Bolden, K.M.; Heller, J.B.; 
Kurkjian, T.J. Anatomy of the supratrochlear nerve: Implications for the surgical treatment of 
migraine headaches. Plast Reconstr. Surg. 2013, 131, 743–750. 
13. Kim, C.C.; Bogart, M.M.; Wee, S.A.; Burstein, R.; Arndt, K.A.; Dover, J.S. Predicting migraine 
responsiveness to botulinum toxin type A injections. Arch. Dermatol. 2010, 146, 159–163. 
14. Levin, M. Nerve blocks in the treatment of headache. Neurotherapeutics 2010, 7, 197–203. 
15. Grazzi, L. Onabotulinum toxin A for treatment of chronic migraine with medication overuse. 
Neurol. Sci. 2013, 34 (Suppl. 1), S27–S28. 
Toxins 2015, 7 2637 
 
 
16. Gerwin, R. Treatment of chronic migraine headache with onabotulinumtoxinA. Curr. Pain 
Headache Rep. 2011, 15, 336–338. 
17. Benecke, R.; Heinze, A.; Reichel, G.; Hefter, H.; Gobel, H.; Dysport myofascial pain study group. 
Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: How do 
fixed-location injections compare with trigger point-focused injections? Pain Med. 2011, 12,  
1607–1614. 
18. Guyuron, B.; Kriegler, J.S.; Davis, J.; Amini, S.B. Comprehensive surgical treatment of migraine 
headaches. Plast Reconstr. Surg. 2005, 115, 1–9. 
19. Fallucco, M.; Janis, J.E.; Hagan, R.R. The anatomical morphology of the supraorbital notch: 
Clinical relevance to the surgical treatment of migraine headaches. Plast Reconstr. Surg. 2012, 130,  
1227–1233. 
20. Afridi, S.K.; Shields, K.G.; Bhola, R.; Goadsby, P.J. Greater occipital nerve injection in primary 
headache syndromes--prolonged effects from a single injection. Pain 2006, 122, 126–129. 
21. Blumenfeld, A.; Ashkenazi, A.; Grosberg, B.; Napchan, U.; Narouze, S.; Nett, B.; DePalma, T.; 
Rosenthal, B.; Tepper, S.; Lipton, R.B. Patterns of use of peripheral nerve blocks and trigger point 
injections among headache practitioners in the USA: Results of the American Headache Society 
Interventional Procedure Survey (AHS-IPS). Headache 2010, 50, 937–942. 
22. Andersen, N.B.; Bovim, G.; Sjaastad, O. The frontotemporal peripheral nerves. Topographic 
variations of the supraorbital, supratrochlear and auriculotemporal nerves and their possible clinical 
significance. Surg. Radiol. Anat. 2001, 23, 97–104. 
23. Konofaos, P.; Soto-Miranda, M.A.; Ver Halen, J.; Fleming, J.C. Supratrochlear and supraorbital 
nerves: An anatomical study and applications in the head and neck area. Ophthal Plast. Reconstr. 
Surg. 2013, 29, 403–408. 
24. Miller, T.A.; Rudkin, G.; Honig, M.; Elahi, M.; Adams, J. Lateral subcutaneous brow lift and 
interbrow muscle resection: Clinical experience and anatomic studies. Plast Reconstr. Surg. 2000, 
105, 1120–1127; discussion 1128. 
25. Janis, J.E.; Ghavami, A.; Lemmon, J.A.; Leedy, J.E.; Guyuron, B. The anatomy of the corrugator 
supercilii muscle: Part II. Supraorbital nerve branching patterns. Plast Reconstr. Surg. 2008, 121, 
233–240. 
26. Aurora, S.K.; Dodick, D.W.; Diener, H.C.; DeGryse, R.E.; Turkel, C.C.; Lipton, R.B.;  
Silberstein, S.D. OnabotulinumtoxinA for chronic migraine: Efficacy, safety, and tolerability in 
patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol. 
Scand. 2014, 129, 61–70. 
27. Aurora, S.K.; Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Silberstein, S.D.; Lipton, R.B.;  
Diener, H.C.; Brin, M.F.; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for 
treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled 
phase of the PREEMPT 1 trial. Cephalalgia 2010, 30, 793–803. 
28. Aurora, S.K.; Winner, P.; Freeman, M.C.; Spierings, E.L.; Heiring, J.O.; DeGryse, R.E.; 
VanDenburgh, A.M.; Nolan, M.E.; Turkel, C.C. OnabotulinumtoxinA for treatment of chronic 
migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache 2011, 51,  
1358–1373. 
Toxins 2015, 7 2638 
 
 
29. Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Aurora, S.K.; Silberstein, S.D.; Lipton, R.B.;  
Diener, H.C.; Brin, M.F.; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for 
treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-
controlled phases of the PREEMPT clinical program. Headache 2010, 50, 921–936. 
30. Ashkenazi, A.; Silberstein, S. Botulinum toxin type A for the treatment of headache: Why we say 
yes. Arch. Neurol. 2008, 65, 146–149. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
